Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECX versus standard pre-operative chemotherapy before resection for resectable oesophageal adenocarcinoma
ISRCTN01852072Phase 3Completed
- Sponsor
- Medical Research Council
- Start
- Nov 2004
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of epirubicin, cisplatin and capecitabine in esophageal adenocarcinoma (EAC) and gastroesophageal adenocarcinoma (2 arms), sponsored by Medical Research Council. Started Nov 2004; status: completed.
02
Drugs
epirubicincisplatincapecitabine
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on ISRCTN01852072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN01852072.